Timothy S. Pardee, MD, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).
Clinical Pearls
Timothy S. Pardee, MD, assistant professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).
24 patients with relapsed or refractory AML received the mitochondrial metabolism inhibitor CPI-613 in combination with high-dose cytarabine and mitoxantrone.
The response rate was 54% (11 complete remissions + 2 complete remissions with incomplete count recovery).
Patients with poor risk cytogenetics tend to respond poorly to chemotherapy.
In this trial, the response rate of patients with poor risk cytogenetics was 53% (7/13).
